- Home
- NNVC
NNVC
NanoViricides Inc.
as 03-28-2025 3:40pm EST
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SHELTON |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $6.50 | AVG Volume (30 days): | 160.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $3.59 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NanoViricides Inc. News
NNVC Breaking Stock News: Dive into NNVC Ticker-Specific Updates for Smart Investing
ACCESS Newswire
18 days ago
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
ACCESS Newswire
25 days ago
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
ACCESS Newswire
a month ago
NanoViricides, Inc. Has Filed its Quarterly Report
Associated Press Finance
a month ago
NanoViricides: Fiscal Q2 Earnings Snapshot
Insider Monkey
a month ago
Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?
ACCESS Newswire
2 months ago
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
ACCESS Newswire
2 months ago
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
ACCESS Newswire
2 months ago
NanoViricides Engages CRO for Phase II Clinical Trial
Compare NNVC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NNVC NanoViricides Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.